Medgenics (MDGN) Misses Q2 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Medgenics Reports Second Quarter 2016 Financial Results
August 4, 2016 8:03 AM EDTPHILADELPHIA, PA -- (Marketwired) -- 08/04/16 -- Medgenics, Inc. (NYSE MKT: MDGN)
Initiated Phase 2/3 study of lead program in mGluR+ ADHD Entered into collaboration for second pediatric product in Inflammatory Bowel Disease Strengthened balance sheet with successful financingMedgenics, Inc. (NYSE MKT: MDGN) (the Company) today announced second quarter 2016 financial results and provided a business update.
"We are very pleased with the... More
